Top headlines: CCI setback for Amazon; 101 Omicron cases in India

The unprecedented step taken by CCI could have far-reaching consequences on Amazon's legal battles with now estranged partner Future

Amazon
BS Web team
2 min read Last Updated : Dec 17 2021 | 6:06 PM IST
CCI suspends Amazon's 2019 deal with Future, imposes Rs 200-cr penalty

India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the US e-commerce giant had concealed information while seeking regulatory approval. It also imposed a Rs 200-crore penalty on Amazon.

The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. Read more

101 Omicron cases in India; time to avoid non-essential travel: Govt

As many as 101 positive cases of the Omicron variant of the coronavirus have been detected across 11 states and union territories so far, the government said on Friday and advised people to keep new year celebrations at low intensity.

It said that though daily COVID-19 cases are below 10,000 for the past 20 days, there is a need to stay vigilant in view of the new variant and rising cases in other countries. Read more

BJP announces alliance with Amarinder Singh for Punjab Assembly polls

The BJP Friday formally announced that it will contest the upcoming assembly elections in Punjab in alliance with Amarinder Singh's Punjab Lok Congress.

Singh on Friday called on the BJP's Punjab incharge and Union minister Gajendra Shekhawat at his residence here. Read more

Sinopharm, J&J, Sputnik vaccines are weaker against Omicron, says report

Covid-19 shots made by China’s state-owned Sinopharm and Johnson & Johnson, as well as the Sputnik vaccine developed by Russia, were found to produce little or no antibodies against omicron in a study, as evidence of the new variant’s vaccine-evading abilities mount.

Researchers at the University of Washington and Swiss drugmaker Humabs Biomed SA analyzed the efficacy of six vaccines against the highly-infectious and most-mutated Covid variant. Read more

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCompetition Commission of IndiaCoronavirus Vaccine

Next Story